NCT04753970 · Phase 1 · RECRUITING
Retina is a Marker for Cerebrovascular Heath
This early trial looks at cilostazol, an existing blood-thinning drug that also widens blood vessels, in people with cerebral small vessel disease. Researchers are measuring blood vessel responses in the brain and retina, and checking safety. It is a Phase 1 trial, meaning an early test of safety and basic effects, not proof that it works.
You may qualify if
- Age ≥18 yo.
- Diagnosis of CADASIL, sporadic WMD or lobar CMB and age-matched healthy controls (eg. patient's spouse or unrelated friends without SVD)
You're excluded if
- Age\<18yo
- Pregnant
- Breast feeding
- Unable to follow commands
- Unable to tolerate MRI
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-08-03